BARD1 抗体
(BRCA1 Associated RING Domain 1 (BARD1))
This gene encodes a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer. [provided by RefSeq, Jul 2008].
| Catalog no. | 产品 | 适用 | 宿主 / 克隆类型 | 应用 | 价格和交货时间 |
|---|---|---|---|---|---|
| BARD1 抗体 (AA 101-200) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 | 人 | 小鼠 Monoclonal |
|
|
|
| BARD1 抗体 (AA 658-757) | 人 | 小鼠 Monoclonal |
|
|
|
| BARD1 抗体 (N-Term) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (AA 1-80) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 | 人 | 小鼠 Monoclonal |
|
|
|
| BARD1 抗体 (AA 428-777) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (N-Term) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (N-Term) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (AA 250-300) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (AA 101-200) (Cy7) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (AA 101-200) (Biotin) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (AA 101-200) (AbBy Fluor® 488) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (AA 101-200) (AbBy Fluor® 555) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (AA 101-200) (AbBy Fluor® 594) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (AA 101-200) (AbBy Fluor® 647) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (AA 101-200) (Cy3) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (AA 101-200) (AbBy Fluor® 750) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (AA 101-200) (AbBy Fluor® 680) | 人 | 兔 Polyclonal |
|
|
|
| BARD1 抗体 (AA 101-200) (AbBy Fluor® 350) | 人 | 兔 Polyclonal |
|
|
Primary Antibody
- IHC (Immunohistochemistry: 有验证图片)
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 所列应用)
- IHC (fro) (Immunohistochemistry (Frozen Sections): 所列应用)
1 reference - 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- ELISA (ELISA: 有验证图片)
- IF (Immunofluorescence: 有验证图片)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- 2A11
- 标记
- unconjugated
- 抗体亚型
- IgG2a
- 抗原表位
- AA 658-757
Primary Antibody
- WB (Western Blotting: 有验证图片)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 克隆
- RB19063
- 标记
- unconjugated
- 抗体亚型
- Ig Fraction
- 抗原表位
- AA 101-131, N-Term
Primary Antibody
- WB (Western Blotting: 有验证图片)
- ELISA (ELISA: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- IF (Immunofluorescence: 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 1-80
Primary Antibody
- WB (Western Blotting: 有验证图片)
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 428-777
Primary Antibody
- WB (Western Blotting: 有验证图片)
- ELISA (ELISA: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- N-Term
Primary Antibody
- WB (Western Blotting: 有验证图片)
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- N-Term
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IP (Immunoprecipitation: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 250-300
Primary Antibody
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- Cy7
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 所列应用)
- IHC (fro) (Immunohistochemistry (Frozen Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- Biotin
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 488
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 555
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 594
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 647
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- Cy3
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 750
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 680
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Primary Antibody
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 350
- 抗体亚型
- IgG
- 抗原表位
- AA 101-200
Latest Publications for our BARD1 抗体
: "FOXK2 transcription factor suppresses ER?-positive breast cancer cell growth through down-regulating the stability of ER? via mechanism involving BRCA1/BARD1." in: Scientific reports, Vol. 5, pp. 8796, (2015) (PubMed).
: "The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function." in: Cellular signalling, Vol. 27, Issue 9, pp. 1763-71, (2015) (PubMed).
: "Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer." in: Breast cancer research and treatment, Vol. 145, Issue 2, pp. 317-30, (2014) (PubMed).
: "SUMOylation proteins in breast cancer." in: Breast cancer research and treatment, Vol. 144, Issue 3, pp. 519-30, (2014) (PubMed).
: "Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. ..." in: Cancer research, Vol. 72, Issue 8, pp. 2068-78, (2012) (PubMed).
: "The in vivo dynamic organization of BRCA1-A complex proteins at DNA damage-induced nuclear foci." in: Traffic (Copenhagen, Denmark), Vol. 13, Issue 6, pp. 800-14, (2012) (PubMed).
: "Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome." in: British journal of cancer, Vol. 107, Issue 4, pp. 675-83, (2012) (PubMed).
: "BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair." in: Journal of cell science, Vol. 125, Issue Pt 15, pp. 3529-34, (2012) (PubMed).
: "HERC2 is an E3 ligase that targets BRCA1 for degradation." in: Cancer research, Vol. 70, Issue 15, pp. 6384-92, (2010) (PubMed).
: "Altered expression of anti-apoptotic proteins in non-involved tissue from cancer-containing breasts." in: Breast cancer research and treatment, Vol. 114, Issue 1, pp. 63-9, (2009) (PubMed).
: "The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function." in: Cellular signalling, Vol. 27, Issue 9, pp. 1763-71, (2015) (PubMed).
: "Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer." in: Breast cancer research and treatment, Vol. 145, Issue 2, pp. 317-30, (2014) (PubMed).
: "SUMOylation proteins in breast cancer." in: Breast cancer research and treatment, Vol. 144, Issue 3, pp. 519-30, (2014) (PubMed).
: "Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. ..." in: Cancer research, Vol. 72, Issue 8, pp. 2068-78, (2012) (PubMed).
: "The in vivo dynamic organization of BRCA1-A complex proteins at DNA damage-induced nuclear foci." in: Traffic (Copenhagen, Denmark), Vol. 13, Issue 6, pp. 800-14, (2012) (PubMed).
: "Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome." in: British journal of cancer, Vol. 107, Issue 4, pp. 675-83, (2012) (PubMed).
: "BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair." in: Journal of cell science, Vol. 125, Issue Pt 15, pp. 3529-34, (2012) (PubMed).
: "HERC2 is an E3 ligase that targets BRCA1 for degradation." in: Cancer research, Vol. 70, Issue 15, pp. 6384-92, (2010) (PubMed).
: "Altered expression of anti-apoptotic proteins in non-involved tissue from cancer-containing breasts." in: Breast cancer research and treatment, Vol. 114, Issue 1, pp. 63-9, (2009) (PubMed).
Aliases for BARD1 抗体
BRCA1 associated RING domain 1 (BARD1) 抗体BRCA1 associated RING domain 1 (bard1) 抗体
BRCA1 associated RING domain 1 (Bard1) 抗体
BARD1 抗体
ENSMUSG00000060893 抗体
ENSMUSG00000073653 抗体
LOC100147913 抗体
您还需要查找其他产品吗？
You are here:
